We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Myriad Genetics (MYGN) Q2 Earnings: What's in the Cards?
Read MoreHide Full Article
Myriad Genetics, Inc. (MYGN - Free Report) is expected to report second-quarter fiscal 2017 results on Feb 7, after the closing bell.
Last quarter, the company posted a negative earnings surprise of 11.54%. However, its earnings outpaced the Zacks Consensus Estimate in two of the last four quarters, with an average beat of 0.21%.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Myriad Genetics is currently plagued by several issues that may hamper its overall performance in the to-be-reported quarter. Of late, the company has been delivering poor hereditary cancer revenue numbers, primarily impacted by volume declines and price reduction. We note that, the reductions in pricing were primarily attributable to the full implementation of long-term contracts that the company signed over the last year.
Although the company expects to see sequential increase in hereditary cancer volumes in the second quarter, we believe there is still time to return to the normal sequential volume trend. From pricing perspective, the company is still not clear about the 35% of revenue that remains under long-term contract.
We remain concerned about the ongoing foreign exchange headwind. With considerable portion of its revenues coming from outside the U.S, the company is at risk of exchange rate fluctuations. Additionally, macroeconomic uncertainty and higher expenses owing to extensive pipeline of some tests may continue to impact the company’s margins in the second quarter.
On a positive note, we are looking forward to Myriad Genetics’ consistent efforts to remain aligned with its five-year goals of achieving revenue growth of greater than 10% CAGR; generating revenues of above $50 million from seven products, operating margins greater than 30% and international revenues constituting more than 10% of total revenue, by 2020.
Management is currently pursuing a number of initiatives to stabilize and grow its hereditary cancer testing business segment. For this, the company earlier submitted data to NCCN on expanding indications in breast cancer and pancreatic cancer. Moreover, recent data on prostate cancer patients and recommendations to expand guidelines to all metastatic patients are expected to considerably expand hereditary cancer indications. Per management, in total, these expansion activities represent more than $1 billion per year in incremental market potential for Myriad. We expect the second quarter to draw some positive outcomes out of these efforts.
Earlier this fiscal, Myriad Genetics completed the acquisition of Assurex, which will boost the former’s preventive care business with the addition of Genesight products that have a market potential of $3 billion. Myriad Genetics expects revenues of approximately $50 million from GeneSight in fiscal 2017. The buyout will also help the company establish the foundation for its neuroscience business which is believed to be one of the highest growth areas for personalized medicine business. We expect to see some favorable outcome from the to-be-reported quarter itself.
Management expects fiscal 2017 to be a year of investment for Myriad Genetics as it looks to expand its footprint with products like Vectra DA, Prolaris and GeneSight, integrate two major acquisitions and also lay the foundation for its companion diagnostic portfolio.
Estimate Revision Trend
If we observe the estimate revision trend for the second quarter over the past one month, we can see that it remains stable with zero upward or downward movements. The magnitude of the estimate revision trend also indicates a stable picture with the second-quarter earnings estimates remaining unchanged at 24 cents, over the last 30 days.
Earnings Whispers
Our quantitative model also doesn’t point to an earnings beat. Here’s why:
Myriad Genetics doesn’t have the right combination of the two key ingredients – positive Earnings ESP and a Zacks Rank #3 (Hold) or better – for increasing the odds of an earnings beat.
Zacks ESP: The Earnings ESP for Myriad Genetics is +4.17%. This is because the Most Accurate estimate of 25 cents remains a penny ahead of the Zacks Consensus Estimate. Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.
Zacks Rank:Myriad Genetics has a Zacks Rank #5 (Strong Sell)
As it is we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
Molina Healthcare Inc. (MOH - Free Report) has an Earnings ESP of +5.33% and a Zacks Rank #2.
Universal Health Services, Inc. (UHS - Free Report) has an Earnings ESP of +4.97% and a Zacks Rank #2.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Myriad Genetics (MYGN) Q2 Earnings: What's in the Cards?
Myriad Genetics, Inc. (MYGN - Free Report) is expected to report second-quarter fiscal 2017 results on Feb 7, after the closing bell.
Last quarter, the company posted a negative earnings surprise of 11.54%. However, its earnings outpaced the Zacks Consensus Estimate in two of the last four quarters, with an average beat of 0.21%.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Myriad Genetics is currently plagued by several issues that may hamper its overall performance in the to-be-reported quarter. Of late, the company has been delivering poor hereditary cancer revenue numbers, primarily impacted by volume declines and price reduction. We note that, the reductions in pricing were primarily attributable to the full implementation of long-term contracts that the company signed over the last year.
Myriad Genetics Inc. Price and EPS Surprise
Myriad Genetics Inc. Price and EPS Surprise | Myriad Genetics Inc. Quote
Although the company expects to see sequential increase in hereditary cancer volumes in the second quarter, we believe there is still time to return to the normal sequential volume trend. From pricing perspective, the company is still not clear about the 35% of revenue that remains under long-term contract.
We remain concerned about the ongoing foreign exchange headwind. With considerable portion of its revenues coming from outside the U.S, the company is at risk of exchange rate fluctuations. Additionally, macroeconomic uncertainty and higher expenses owing to extensive pipeline of some tests may continue to impact the company’s margins in the second quarter.
On a positive note, we are looking forward to Myriad Genetics’ consistent efforts to remain aligned with its five-year goals of achieving revenue growth of greater than 10% CAGR; generating revenues of above $50 million from seven products, operating margins greater than 30% and international revenues constituting more than 10% of total revenue, by 2020.
Management is currently pursuing a number of initiatives to stabilize and grow its hereditary cancer testing business segment. For this, the company earlier submitted data to NCCN on expanding indications in breast cancer and pancreatic cancer. Moreover, recent data on prostate cancer patients and recommendations to expand guidelines to all metastatic patients are expected to considerably expand hereditary cancer indications. Per management, in total, these expansion activities represent more than $1 billion per year in incremental market potential for Myriad. We expect the second quarter to draw some positive outcomes out of these efforts.
Earlier this fiscal, Myriad Genetics completed the acquisition of Assurex, which will boost the former’s preventive care business with the addition of Genesight products that have a market potential of $3 billion. Myriad Genetics expects revenues of approximately $50 million from GeneSight in fiscal 2017. The buyout will also help the company establish the foundation for its neuroscience business which is believed to be one of the highest growth areas for personalized medicine business. We expect to see some favorable outcome from the to-be-reported quarter itself.
Management expects fiscal 2017 to be a year of investment for Myriad Genetics as it looks to expand its footprint with products like Vectra DA, Prolaris and GeneSight, integrate two major acquisitions and also lay the foundation for its companion diagnostic portfolio.
Estimate Revision Trend
If we observe the estimate revision trend for the second quarter over the past one month, we can see that it remains stable with zero upward or downward movements. The magnitude of the estimate revision trend also indicates a stable picture with the second-quarter earnings estimates remaining unchanged at 24 cents, over the last 30 days.
Earnings Whispers
Our quantitative model also doesn’t point to an earnings beat. Here’s why:
Myriad Genetics doesn’t have the right combination of the two key ingredients – positive Earnings ESP and a Zacks Rank #3 (Hold) or better – for increasing the odds of an earnings beat.
Zacks ESP: The Earnings ESP for Myriad Genetics is +4.17%. This is because the Most Accurate estimate of 25 cents remains a penny ahead of the Zacks Consensus Estimate. Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.
Zacks Rank:Myriad Genetics has a Zacks Rank #5 (Strong Sell)
As it is we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
Cempra Inc. has an Earnings ESP of +15.79% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Molina Healthcare Inc. (MOH - Free Report) has an Earnings ESP of +5.33% and a Zacks Rank #2.
Universal Health Services, Inc. (UHS - Free Report) has an Earnings ESP of +4.97% and a Zacks Rank #2.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>